Publicly traded Novavax, Inc. (NASDAQ: NVAX) has enrolled its first participants in a Phase I/II clinical trial of its SARS-CoV-2 vaccine candidate called NVX-CoV2373, a stable, prefusion protein made using the company’s proprietary nanoparticle technology. The...
Nucleus Network
Category
Australian-based Nucleus Network Led Phase I Shows Results for Muscular Sclerosis & Systemic Scleroderma
A first-in-human clinical trial of an investigational treatment for muscular sclerosis (MS) and systemic scleroderma (SSc) called EHP-101 was successfully completed. The Phase I clinical trial sponsored by Emerald Health Pharmaceuticals (EHP) demonstrated that EHP-101...